AbCellera Biologics Inc. has entered into a collaboration agreement with Vertex Pharmaceuticals to discover, develop, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera will lead early discovery and development using its proprietary TCE platform.
Key Details
- Agreement: The collaboration focuses on leveraging AbCellera's TCE platform to develop new therapies for autoimmune diseases.
- Financial Terms: AbCellera will receive $28 million in total upfront payments. The company is also eligible for future preclinical, development, regulatory, and commercial milestone payments, as well as tiered royalties on net sales.
- Responsibilities: AbCellera will conduct discovery and early development activities. Vertex will fund all research and development costs and will hold the rights to develop and commercialize any resulting therapeutic antibodies.